All the news Showing 10 of 82 articles from: Protease inhibitorsGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources J&J-Medivir Drug for Hepatitis C Recommended by EU Regulator Bloomberg Businessweek / 21 March 2014 New Phase III Data from Once-Daily Simeprevir Presented at the Conference of the Asian Pacific Association for the Study of the Liver (APASL) Medivir press release / 17 March 2014 Treating HCV -- Is the Price Right? Med Page Today / 19 February 2014 AbbVie Completes Largest Phase III Program of an All-Oral, Interferon-Free Therapy for the Treatment of Hepatitis C Genotype 1 AbbVie press release / 31 January 2014 Hep C drug deleobuvir pulled from clinical study, citing high rate of early discontinuations Project Inform / 21 January 2014 Experimental treatment cures Ottawa wrestler of hepatitis C CBC / 14 January 2014 Achillion Reports HCV Pipeline Progress and Outlines 2014 HCV Milestones Achillion press release / 14 January 2014 Phase III data show Boehringer Ingelheim’s faldaprevir is effective even in patients with common drug-resistant viral variant Boehringer-Ingelheim press release / 16 December 2013 An all-oral phase IIa study combining Simeprevir, TMC647055 and JNJ56914845 in hepatitis C patients to be initiated Medivir press release / 16 December 2013 AbbVie Demonstrates 96 percent SVR(12) in its Phase III Study of Treatment-Experienced Patients with Genotype 1 Hepatitis C AbbVie press release / 10 December 2013 ← Prev1...23456...9Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive